Is there an ototoxicity risk from cortisporin and comparable otic suspensions? Distortion-product otoacoustic emission findings

Ear, Nose and Throat Journal

Volumn 91, Issue 3, 2012, Pages 106-113

  Berenholz, Leonard P ^a   Rossi, Dyana L ^a   Lippy, William H ^a   Burkey, John M ^a  

^a Lippy Group for ENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEOMYCIN PLUS POLYMYXIN B PLUS HYDROCORTISONE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DRUG SAFETY; FEMALE; HUMAN; INFANT; MALE; OTOTOXICITY; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; SCHOOL CHILD;

EID: 84861486945     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556131209100307     Document Type: Article

References (19)

1. Roland PS, Rybak L, Hannley M, et al. Animal ototoxicity of topical antibiotics and the relevance to clinical treatment of human subjects. Otolaryngol Head Neck Surg 2004; 130 (3 Suppl): S57-78.
2. Roland PS. Clinical ototoxicity of topical antibiotic drops. Otolaryngol Head Neck Surg 1994; 110 (6): 598-602.
3. Matz G, Rybak L, Roland PS, et al. Ototoxicity of ototopical antibiotic drops in humans. Otolaryngol Head Neck Surg 2004; 130 (3 Suppl): S79-82.
4. Berenholz LP, Burkey JM, Farmer TL, Lippy WH. Topical otic antibiotics: Clinical cochlear ototoxicity and cost consideration. Otolaryngol Head Neck Surg 2006; 135 (2): 291-4.
5. Rutka J. How serious a problem is topical aminoglycoside ototoxicity? Ear Nose Throat J 2006; 85 (10 Suppl 1): 19-21.
6. Ress BD, Sridhar KS, Balkany TJ, et al. Effects of cis-platinum chemotherapy on otoacoustic emissions: The development of an objective screening protocol. Otolaryngol Head Neck Surg 1999; 121 (6): 693-701.
7. Stavroulaki P, Vossinakis IC, Dinopoulou D, et al. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Arch Otolaryngol Head Neck Surg 2002; 128 (2): 150-5.
8. Stavroulaki P, Apostolopoulos N, Segas J, et al. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 2001; 59 (1): 47-57.
9. Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25 (10): 1190-5.
10. Topolska MM, Hassman E, Baczek M. The effects of chronic otitis media with effusion on the measurement of distortion products of otoacoustic emissions: Presurgical and postsurgical examination. Clin Otolaryngol Allied Sci 2000; 25 (4): 315-20.
11. Owens JJ, McCoy MJ, Lonsbury-Martin BL, Martin GK. Otoacoustic emissions in children with normal ears, middle ear dysfunction, and ventilating tubes. Am J Otol 1993; 14 (1): 34-40.
12. Welling DB, Forrest LA, Goll F III. Safety of ototopical antibiotics. Laryngoscope 1995; 105 (5 Pt 1): 472-4.
13. Rakover Y, Keywan K, Rosen G. Safety of topical ear drops containing ototoxic antibiotics. J Otolaryngol 1997; 26 (3): 194-6.
14. Meyerhoff WL, Morizono T, Wright CG, et al. Tympanostomy tubes and otic drops. Laryngoscope 1983; 93 (8): 1022-7.
15. Morizono T. Toxicity of ototopical drugs: Animal modeling. Ann Otol Rhinol Laryngol Suppl 1990; 148:42-5.
16. Haynes DS, Rutka J, Hawke M, Rolad PS. Ototoxicity of ototopical drops-an update. Otolaryngol Clin North Am 2007; 40 (3): 669-83, xi.
17. Rutka J. Other topical agents are safer and just as effective. Ear Nose Throat J 2003; 82 (Suppl 1): 15.
18. Morpeth JF, Bent JP, Watson T. A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea. Int J Pediatr Otorhinolaryngol 2001; 61 (2): 99-104.
19. Poetker DM, Lindstrom DR, Patel NJ, et al. Ofloxacin otic drops vs neomycin-polymyxin B otic drops as prophylaxis against early postoperative tympanostomy tube otorrhea. Arch Otolaryngol Head Neck Surg 2006; 132 (12): 1294-8.